Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunmax Biotechnology CoROCO:4728 91 Debt-to-EBITDA is 0.07 as of Jun. 2026, which is 68% below its 10-year median of 0.22. GuruFocus rates ROCO:4728 with a GF Score™ of 91/100 and a GF Value™ of NT$405.54 (Fairly Valued). The stock has 2 warning signs investors should review. Among 318 Biotechnology companies, Sunmax Biotechnology Co ranks better than 86.16% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Sunmax Biotechnology Co's Debt-to-EBITDA or its related term are showing as below:
ROCO:4728'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.08 Med: 0.22 Max: 1.15
Current: 0.09
During the past 13 years, the highest Debt-to-EBITDA Ratio of Sunmax Biotechnology Co was 1.15. The lowest was 0.08. And the median was 0.22.
ROCO:4728's Debt-to-EBITDA is ranked better than 86.16% of 318
companies
in the Biotechnology industry
Industry Median: 1.27
vs ROCO:4728: 0.09
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Sunmax Biotechnology Co Debt-to-EBITDA Related Terms
Sunmax Biotechnology Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4728 vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Sunmax Biotechnology Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunmax Biotechnology Co Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sunmax Biotechnology Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sunmax Biotechnology Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Sunmax Biotechnology Co (ROCO:4728) has a Debt-to-EBITDA of 0.07 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sunmax Biotechnology Co. This is 68% below median its historical median of 0.22. Over the past decade, Sunmax Biotechnology Co's Debt-to-EBITDA has ranged from 0.08 to 1.15. According to the industry distribution chart, Sunmax Biotechnology Co ranks #44 out of 318 companies in the Biotechnology industry, placing it in the top 13.8%.
Is Sunmax Biotechnology Co's Debt-to-EBITDA too high?
Sunmax Biotechnology Co's current Debt-to-EBITDA of 0.07 is 68% below median its 10-year median of 0.22. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 1.15. The Biotechnology industry median Debt-to-EBITDA is 1.27. Sunmax Biotechnology Co's value of 0.07 is 94.5% below this industry median. Based on the distribution chart, Sunmax Biotechnology Co ranks #44 out of 318 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sunmax Biotechnology Co has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sunmax Biotechnology Co's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sunmax Biotechnology Co ranks #44 out of 318 companies for Debt-to-EBITDA. This places Sunmax Biotechnology Co in the top 14% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.27. Sunmax Biotechnology Co's value of 0.07 is 94.5% below this benchmark. Historically, Sunmax Biotechnology Co's own Debt-to-EBITDA has ranged from 0.08 to 1.15 over the past decade. While the company's 10-year median is 0.22 vs. the industry median of 1.27, Sunmax Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.27, based on 318 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunmax Biotechnology Co's current Debt-to-EBITDA of 0.07 is 94.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sunmax Biotechnology Co. For the Biotechnology industry, the median Debt-to-EBITDA is 1.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunmax Biotechnology Co's current Debt-to-EBITDA is 0.07, which is 68% below median its own 10-year median of 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunmax Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Sunmax Biotechnology Co (ROCO:4728) is currently considered Fairly Valued. The stock's GF Value™ is NT$405.54, compared to a current price of NT$400.00 — trading 1.4% below its estimated fair value. The current Debt-to-EBITDA is 0.07, which is 68% below median its 10-year median of 0.22 and 94.5% below the Biotechnology industry median of 1.27. Sunmax Biotechnology Co's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Sunmax Biotechnology Co (ROCO:4728), the current Debt-to-EBITDA is 0.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunmax Biotechnology Co (ROCO:4728) Overvalued in 2026?
Based on GuruFocus' analysis, Sunmax Biotechnology Co stock appears to be undervalued.
The current stock price of NT$400.00 is trading 1.4% below its estimated GF Value™ of NT$405.54.
GuruFocus considers Sunmax Biotechnology Co to be Fairly Valued.
Key valuation signals for ROCO:4728:
Debt-to-EBITDA: 0.07 (68% below median its 10-year median of 0.22)
GF Value™: NT$405.54 vs. price of NT$400.00 (1.4% below fair value)
Industry Position: 94.5% below the Biotechnology median (#44 of 318)
No single metric tells the full story. See the ROCO:4728 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunmax Biotechnology Co Ltd is a biomedical company in Taiwan. It is engaged in the development, manufacturing, and commercialization of Sunmax medical devices and bio-surgical products. Additionally, it also researches, develops, manufactures and sales biomedical material grade collagen and related products. The company's products include medical products, biomedical materials, and porcine collagen skin care products.
91GF Score
Get the complete analysis for ROCO:4728
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4728 has been successfully added to your 
